医学
围手术期
布鲁顿酪氨酸激酶
血管成形术
不利影响
血运重建
内科学
外科
酪氨酸激酶
受体
心肌梗塞
作者
Apostolos G. Pitoulias,Georgios A. Pitoulias
标识
DOI:10.23736/s0021-9509.21.12113-5
摘要
Based in low-quality evidence, it seems that ATH in BTK vessels has a high safety, high efficacy profile and durable outcomes at 12 months. In the mid-term, the clinical success of ATH is compromised by increased TLR and MALEs rates. Comparison of ATH with other endovascular techniques in BTK treatment of PAD shows a slight lead of ATH at 1-year and equivalent clinical performance in the mid-term. Overall, ATH has a significant and potentially predominant role in treatment of BTK vessels.
科研通智能强力驱动
Strongly Powered by AbleSci AI